



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

14th May 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Advertisement relating to Financial Results

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of Audited Financial Results for quarter & year ended 31st March 2025.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl: Public Notice

CIN: L24239MH1924PLC001151

15
Around the World

DEAL INCLUDES \$142B DEFENCE PACT, ENERGY-MINING PARTNERSHIP

Trump's Take Home from Saudi Arabia: \$600-b Investment Commitment

We like each other a lot, US President tells Prince Salman

Riyadh: US President Donald Trump secured a \$600 billion commitment from Saudi Arabia on Tuesday to invest in the United States after the oil power rolled out the red carpet for him at the start of a tour of Gulf states.

Trump punched the air as he emerged from Air Force One to be greeted by Prince Mohammed bin Salman, who later signed an agreement with the president in Riyadh on energy, defence, mining and other areas.

Saudi Arabia's investment commitment includes what the US described as the largest defence sales agreement between the allies, worth nearly \$142 billion.

Reuters reported in April the US was poised to offer the kingdom an arms package worth well over \$100 billion. "I really believe we like each other a lot," Trump said during a meeting with the crown prince, Saudi Arabia's de facto ruler.

The US and Saudi Arabia had discussed Riyadh's potential purchase of Lockheed F-35 jets, two sources briefed on discussions told Reuters, referring to a military aircraft that the kingdom is long thought to have been interested in.

It was not immediately clear whether those aircraft were covered in the deal announced between the nations on Tuesday.

Trump, who is accompanied by US business leaders including billionaire Elon Musk, will go on from Riyadh to Qatar on Wednesday and the United Arab Emirates on Thursday.

He has not scheduled a stop in Israel, a decision that has raised questions about where the close ally stands in Washington's priorities, and the focus



of the trip is on investment rather than security matters in the Middle East.

"While energy remains a cornerstone of our relationship, the investments and business opportunities in the kingdom have expanded and multiplied many, many times over," Saudi investment minister Khalid al-Falih told a U.S.-Saudi investment forum.

"As a result ... when Saudis and Americans join forces very good things happen, more often than not great things happen when those joint ventures happen," he said before Trump's arrival.

Trump called the Saudi crown prince a friend and said they have a good relationship, according to a pool report from the Wall Street Journal, adding that Saudi investment would help create jobs in the U.S.

the crown prince, who is otherwise known as MbS, during a palace reception for the U.S. president. And joining Trump for a lunch with MbS were top U.S. businessmen including Musk, the Tesla and SpaceX chief, and OpenAI CEO Sam Altman.

WILL EASE SANCTIONS ON SYRIA

Trump also said on Tuesday that he will move to normalise relations and lift sanctions on Syria's new government to give the country "a chance at peace." Trump was set to meet Wednesday in Saudi Arabia with Syrian President Ahmad al-Sharaa, the onetime insurgent who last year led the overthrow of former leader Bashar Assad. Agencies

US April Inflation Cools as Some Tariffs Take Effect

Washington: Inflation cooled for the third straight month in April even after some of President Donald Trump's tariffs took effect, though economists and many business owners expect inflation will climb in the coming months.

Consumer prices rose 2.3% in April from a year ago, the Labor Department said Tuesday, down from 2.4% in March and the smallest increase in more than four years.

On a monthly basis, prices rose modestly, increasing 0.2% from March to April after falling 0.1% the previous month, the first drop in five years.

Grocery prices dipped 0.4% from March to April in what will come as a relief to many people stretching family budgets for the basics. It was the biggest decline in food costs at home since September 2020, the government said. Egg prices fell sharply, declining 12.7%, the most in 41 years. Yet they are still 49%

higher than a year ago. The report suggests the tariffs haven't yet impacted the prices of many items. Clothing costs fell 0.2% from March to April, while new car prices were unchanged. Furniture costs jumped 1.5%, however.

Excluding the volatile food and energy categories, core prices were also muted, rising 2.8% in April compared with a year ago, the same as in March. On a monthly basis, they increased a mild 0.2%. Economists watch core prices because they typically provide a better read on where prices are headed.

Only some early tariffs imposed by Trump were in effect in April, including 25% duties on steel and aluminum and 25% on some imports from Canada and Mexico. AP

US Cuts Tariff on China Low-value Items to 54%

Hong Kong | Shanghai: The United States will cut the "de minimis" tariff for low-value items imported from China, a White House executive order said late on Monday, further de-escalating a potentially damaging trade war between the world's two largest economies.



The tariff relief, which affects big Chinese e-commerce players including Shein and Temu, follows a deal between Beijing and Washington to unwind most of the duties imposed on each other's goods since early April, after weekend talks in Geneva.

While their joint statement in Geneva didn't mention the de minimis duties, the White House order released later said the levies will be reduced to 54% from 120% for items valued at up to \$900 sent from China via postal services, with a flat fee of \$100 to remain, starting from May 14.

Carriers can pay either the 54% or the \$100 fee per package, industry experts said. The logistics companies or freight forwarders collect those tariff fees from sellers in China in advance. The de minimis exemption allowed items valued at up to \$800

and sent from China via postal service to previously enter the US duty free and with minimal inspections.

In February, President Donald Trump ended the de minimis exemption by imposing a tax of 120% of the package's value or a planned flat fee of \$200.

BOEING CAN FLY

China has removed a ban on airlines taking delivery of Boeing planes after the United States and China agreed a temporary cut in steep tariffs, Bloomberg News reported on Tuesday, citing sources familiar with the matter.

Officials in Beijing have started to tell domestic carriers and government agencies this week that deliveries of aircraft made in the US can resume, the report said. Agencies



BLISS GVS PHARMA LIMITED

CIN No - L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Saki Naka Road, Saki Vihar, Andheri (East), Mumbai - 400 072.
• Email: cs@blissgvs.com • Website: www.blissgvs.com

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

The Board of Directors of the Company, at their meeting held on Monday, May 12, 2025 approved the audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2025.

The full format of the financial results of the Company, are available on the Stock Exchanges websites at www.bseindia.com and www.nseindia.com and are also posted on the Company's website at <https://blissgvs.com/investors/financials/quarterly-reports/> which can be accessed by scanning the Quick Response (QR) code.



For BLISS GVS PHARMA LIMITED
SD/-
GAGAN HARSH SHARMA
MANAGING DIRECTOR
Din : 07939421

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 • Website: <https://india-pharma.gsk.com/en-in/>
Email: investorquery@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

(₹ In Lakhs)

Particulars	Standalone					Consolidated				
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
1 Revenue from continuing operations	96608	94636	91087	372349	340725	97437	94942	92980	374921	345371
2 Profit before Exceptional Items and tax	35490	30635	26631	124375	95265	35857	30810	26822	125519	95980
3 Exceptional Items [credit / (charge)]	-	-	240	469	(14361)	-	-	240	469	(14361)
4 Profit before tax	35490	30635	26871	124844	80904	35857	30810	27062	125988	81619
5 Net Profit after tax	26014	22858	19308	91906	58469	26287	22988	19448	92758	58996
6 Total comprehensive income for the period	25630	22976	19239	91640	58052	25903	23106	19379	92492	58579
7 Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8 Other Equity	-	-	-	177982	161468	-	-	-	178190	160823
9 Earnings Per Share (EPS) (of ₹ 10 each)										
Basic and diluted EPS before Exceptional Items (₹)	15.35	13.49	11.29	54.01	40.83	15.52	13.57	11.37	54.52	41.14
Basic and diluted EPS after Exceptional Items (₹)	15.35	13.49	11.39	54.24	34.51	15.52	13.57	11.48	54.76	34.83
	Not Annualised					Not Annualised				

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th May, 2025.
- The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs. 32 per equity share).



Place: Mumbai
Date: 13th May, 2025

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346



SIYARAM SILK MILLS LTD.

CIN : L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),
Phone - 022-3040 0500; Email - sharedept@siyaram.com; Website - www.siyaram.com

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025.

(₹ In Lakhs)

PARTICULARS	STANDALONE					CONSOLIDATED				
	Quarter Ended		Year Ended			Quarter Ended		Year Ended		
	31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)
Revenue from Operations	73607.75	57017.36	64636.93	222031.86	208717.60	73,619.22	57,072.91	64,777.49	2,22,161.91	2,09,205.46
Other Income	1359.36	1622.93	640.58	7530.08	3754.55	1,359.54	1,622.93	640.52	7,532.89	3,759.75
Total Income	74967.11	58640.29	65277.51	229561.94	212472.15	74,978.76	58,695.84	65,418.01	2,29,694.80	2,12,965.21
Net Profit for the period Before Tax	10014.77	6212.56	9316.88	26894.22	24707.61	9,974.52	6,165.11	9,321.41	26,732.58	24,715.25
Net Profit for the period After Tax	7127.57	4583.96	6910.58	19747.43	18456.60	7,101.03	4,542.87	6,909.72	19,598.16	18,466.49
Paid up Equity Share Capital (Face value of ₹ 2/- per share)	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40
Earnings Per Share (of ₹ 2/- each)										
Basic and Diluted (₹) (not annualised)	15.97	10.11	14.93	43.80	39.98	15.88	10.01	14.94	43.45	39.99

Notes:

- The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These Financial Results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting practices and policies to the extent applicable.
- The Board has recommended Final Dividend of ₹ 5/- (250%) per equity share of ₹ 2/- each, subject to approval of Shareholders at ensuing Annual General Meeting.
- The above is an extract of the detailed format of Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.siyaram.com



Place: Mumbai
Date: 12/05/2025

For SIYARAM SILK MILLS LTD.
Sd/-
(Ramesh Poddar)
Chairman & Managing Director
DIN : 00090104



Lack of growth triggers to weigh on Dr Reddy's

Lower margins also a key concern; stock has been underperformer in short, long term

RAM PRASAD SAHU
Mumbai, 13 May

Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "sell" or "reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term. While the peer index, Nifty Pharma, has delivered a 70 per cent return over the past two years, the drug major's returns are at 20 per cent.


Near-term disappointment has been the margin performance in Q4. Gross margins were down 262 basis points (bps) sequentially, and fell over 400 bps compared to the year-ago quarter. This is the third consecutive fall in gross margins for Dr Reddy's.

Shashank Krishnakumar and Bhavya Gandhi of Emkay Research point out that the sharp sequential decline in gross margins validates their concern since Q2FY25 that gross margin might be on a secular downward trajectory.

While the gross margin decline in Q4 was partly attributed to one-offs, the weakness is also a function of incremental pricing pressures in the core US portfolio, particularly the generic version of Subrozone (for opioid use disorder), the largest contributor after generic variant of cancer drug



UNDER PRESSURE



Revlimid. The brokerage has a "reduce" rating, with a target price of ₹1,050.

Its ability to maintain growth engines, given the impending dip in Revlimid sales (patent expiry in January 2026), is another key worry and will remain an overhang. After a lacklustre approval rate for key drugs in the last five years, the company is eyeing over 20 major launches in the US market over the next four years. Gaurav Tinani of Antique Stock Broking believes that the company has a tough transition ahead as it is in the early stages of a growth rebuild, aiming to counter the anticipated decline in Revlimid sales.

This transition involves navigating the complexities of development, timeline uncertainties for market formation for limited competition biosimilar opportunities, and higher associated costs. The

brokerage estimates operating profit margin to be 22.3 per cent for FY27, compared to the management's target of 25 per cent. It has maintained a "sell" rating on the stock, with a target price of ₹1,025.

Growth in the domestic market will be another concern area. The company's India business revenue grew by 16 per cent year-on-year (Y-o-Y), largely driven by the vaccine portfolio incensed from Sanofi, new product launches, and price increases. This was partially offset by lower volumes.

Excluding the Sanofi portfolio, domestic sales grew by just 6 per cent in the quarter due to headwinds in cardiac and gastrointestinal therapies. Analysts led by Alankar Garude of Kotak Institutional Equities pointed out that the company's domestic sales have demonstrated a seemingly healthy 10.5 per cent growth annually over FY17-FY24. However, adjusted for incensing, acquisitions and divestments, Dr Reddy's like-for-like organic domestic sales over FY17-FY24 is merely 7.5 per cent, they added.

The brokerage has a "reduce" rating, with a target price of ₹1,180. At current market prices, they believe the US pricing stability, upside in emerging markets from blood sugar-control formulation GLP-1 or glucagon-like peptide-1, and healthy growth in the EU are priced in.



DEFENCE FUNDS

Valuation risk: Avoid entering or do so via SIP with 10-yr horizon

SANJAY KUMAR SINGH

Investment Research India.

The Nifty India Defence Total Return Index (TRI) has risen 27.4 per cent over the past three months, outperforming the Nifty 50 TRI, which gained 8.2 per cent. Defence-focused mutual funds have mirrored this rally. The category includes one active fund, HDFC Defence Fund, with assets under management (AUM) of ₹5,487.27 crore, and passive schemes from three fund houses — Motilal Oswal, Aditya Birla Sun Life, and Groww. These schemes manage ₹9,133.82 crore collectively.

These funds invest in defence equipment and other stocks related to the defence sector. "A look at the Nifty India Defence Index's constituents reveals that it is a highly concentrated, top-heavy index. There is also a paucity of listed names in this space," says Kautubh Belapurkar, director-manager research, Morningstar

Sound prospects

Jefferies estimates India's defence sector opportunity at \$100–120 billion over the next five-six years, with growth projected at 13 per cent compounded annually from financial year (FY) 2022-23 to FY2030. In FY24, domestic defence production reached a record ₹1.3 trillion.

"With the trend of protectionism in defence spreading globally, the Indian government has launched the Make in India

initiative in the defence sector, which is a key driver for its growth," says Vishal Dhawan, chief financial planner, Plan Ahead Wealth Advisors.

The recent border tensions with Pakistan could lead to a spike in India's defence budget. "This would mean higher revenues and profits for the companies in this sector," says Abhishek Kumar, Securities and Exchange Board of India (Sebi) registered investment advisor and founder, SahajMoney.com. He adds that investing in these funds may also help investors diversify their portfolios beyond traditional sectors.

Concentration, valuation risk

Defence funds carry high concentration risk. "Both the index and the active fund in this space are driven by just a few stocks," says Belapurkar.

Heavy inflows have driven many defence stocks up by 60–70 per cent annually over five years, leading to expensive valuations. "The current price-to-earnings (P/E) ratio of the Nifty 50 is 22, while the Nifty India Defence Index is at 52. The price-to-book value for the two

indices is 4 and 13 respectively. Thus, the Nifty Defence Index's valuations are more than two-three times the Nifty 50's," says Dhawan.

HDFC Defence Fund stopped accepting investments in mid-2024 — a development that investors should regard as a cautionary signal.

While defence firms are winning large orders, these typically take years to convert into revenue. "This could create a mismatch between the size of the order book and immediate profitability," says Dhawan.

Kumar highlights that these funds could take a hit if defence spending slows or due to elevated valuations.


Right time to enter?

Given the sharp run-up, most investors should avoid entering now. Only those with a strong fundamental view of the sector and its companies should invest. "These investors will have to be extremely patient and must be ready to ride out a down cycle before the sector moves up again," says Belapurkar.

Dhawan adds that only experienced investors with a high risk appetite, a grasp of market cycles, and comfort with volatility and timing risk should invest. Kumar cautions that conservative or inexperienced investors, those seeking stable returns, or those with short-term goals should stay away. Exposure to these funds should be taken in the satellite portfolio and limited to 5 per cent. Stagger your entry and have a minimum horizon of 10 years.

DEFENCE INDEX: ENJOYING A HOT STREAK

Returns (%) ■ Nifty 50 TRI ■ Nifty India Defence TRI



Got a tax notice for a sudden income spike? What you must do

A notice from the income-tax department under Section 133(6) of the Income-tax Act, 1961 is commonly sent when there are high-value transactions, sudden income spikes, or large deductions that appear inconsistent with the income reported by the taxpayer. If you get one such notice, don't panic.

Steps to follow after receiving the notice

Ankit Jain, partner at Ved Jain and Associates, says that the taxpayer should follow a structured response: **VERIFY THE NOTICE:** Ensure it has been issued by a valid income tax officer and carries a Document Identification Number.

UNDERSTAND THE REQUIREMENT: Read the notice carefully to determine the scope and type of information requested.

COMPILE DOCUMENTS: Gather all relevant data and check for accuracy.

SUBMIT THE RESPONSE: The information should be furnished via the Income Tax e-filing portal.

SEEK MORE TIME IF NEEDED: If doc-

uments can't be provided within the deadline, Jain advised sending a formal request for extension.

How to avoid receiving one in the first place

Naveen Wadhwa, vice-president at Taxmann, recommended maintaining financial transparency.

Read full report here: mybs.in/2en0iex

COMPILED BY AMIT KUMAR



एसजेवीएन लिमिटेड SJVN Limited
(भारत सरकार एवं हिमाचल प्रदेश सरकार का संयुक्त उपक्रम)
(A Joint Venture of Govt. of India & Govt. of H.P.)
CIN No. L40101HP1989G0108409

Notice Inviting Tender (NIT)
NIT No: SJVN/CC-Delhi/LO/C&P/4434 Date: 13.05.2025
SJVN Limited hereby invites **ONLINE** bids from the eligible bidders for **"One-time Remedial Contract for Supply of materials, repair/restoration, testing and commissioning of 4 Nos WTGs of SJVN's 47.60 MW (56 x850 kW) Khirvire Wind Power Station (KWPS) at Khirvire/Kombhaine site, District Ahmednagar in the State of Maharashtra"**. The NIT Document can be downloaded from the websites www.sjvn.nic.in, www.eprocure.gov.in and **GEM portal (Bid No. GEM/2025/B/6227300 dt 13/5/2025)** from **13.05.2025 to 03.06.2025 till 14:00 Hrs (IST)**. The Bid is to be submitted **ONLINE** on the **GEM Portal** i.e. <https://gem.gov.in>. The prospective bidders are requested to remain updated through above mentioned websites for any clarification or notification concerned with this NIT, as no further information will be published in respect of this NIT through any other media.
Last Date & Time for submission of bids : 03.06.2025 till 14:00 Hrs
Date & Time of opening of bids : 03.06.2025 at 15:00 Hrs
Dy. General Manager (C&P)
6th Floor, Tower1, NBCC Office Complex, East Kidwai Nagar,
New Delhi-110023. Ph.: 011-61501906 / 61901953

Our Shared Vision: 25000 MW by 2030; 50000 MW by 2040

SHOPPING MALL AVAILABLE FOR SALE IN PERAMBUR, CHENNAI

Spectrum mall - 60% stake [5 screens currently operated by PVR Cinemas on lease + shopping area] along with two vacant lands (Palikaranai & Market Street, Perambur) and 8 residential flats are available for E-auction under IBC, 2016.

[Ganga Foundations Private Limited]
E-auction date : 18th June 2025
Contact Liquidator for further details :
CA Mahalingam Suresh Kumar / gfpl.liq@gmail.com/
Ph : +91 94888 10404



STATE BANK OF INDIA
Premises & Estate Dept., Local Head Office,
2nd Floor, III/1, Pt. J. N. Marg, Bhubaneswar-751001,
Ph. No. : 0674-2394637, E-mail: agmpre.lhobhu@sbi.co.in


TENDER NO: BHU/P&E/2025-2016, DATED: 13.05.2025
PRE-QUALIFICATION AND SELECTION OF ARCHITECTURAL CONSULTANCY FIRM (CONSULTANT) THROUGH DESIGN COMPETITION FOR CONSTRUCTION OF BANK'S MULTI STORED (B+S+4) BUILDING ON VACANT PLOT AT IDCO PLOT, MANCHESWAR I.E. BHUBANESWAR UNDER BHUBANESWAR CIRCLE.
Premises & Estate Department, on behalf of SBI, invites offer in two bid system for appointment of Architectural Consultancy Firm (Consultant) through design competition for upcoming construction of Bank's multi-storey building (B+S+4) to accommodate **L&PC, CCPC, CPCC & I-DAC at MANCHESWAR I.E. Bhubaneswar, Khurda district, Odisha**. The eligible and interested parties may download the prescribed application form from the Bank's **website: "Bank.sbi->SBI in the news->Procurement news"**. The applications can be downloaded from **14.05.2025 to 04.06.2025 up to 15.00 Hrs** and completely filled in application in the prescribed format along with all supporting documents should reach us in the aforesaid address on or before due date & time. The Bank reserves the right to reject/accept any or all the offers received without assigning any reason thereof. The addendum/ corrigendum, if any will be published in the Bank's Website only.
Place: Bhubaneswar, Date: 14.05.2025 Asst. General Manager (P&E)

FORM NO. CAA 2
[Pursuant to Section 230(3) of the Companies Act, 2013 and Rule 6 and 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016]

BEFORE THE NATIONAL COMPANY LAW TRIBUNAL DIVISION BENCH-II, CHENNAI. CA(CAA)/16(CHE)/2025
In the matter of Composite Scheme of Arrangement and Amalgamation Between Cura Healthcare Private Limited (Demerged Company) And Adonis Medical Systems Private Limited (Resulting/Transferee/Amalgamated Company) And 3l Medical Technologies Private Limited (Transferor/Amalgamating Company) And Their respective shareholders and creditors
Adonis Medical Systems Private Limited, (CIN: U51397TN1998PTC121627) a Company incorporated under the Companies Act, 1956, having its Registered Office at Refex Towers, 2nd Floor, 313, Valluvar Kottam High Road, Sterling Road Signal, Nungambakkam, Chennai, Tamil Nadu 600034
... **2nd Appointed/Resulting/Transferee/Amalgamated Company**

ADVERTISEMENT OF NOTICE OF THE MEETING OF THE UNSECURED CREDITORS OF ADONIS MEDICAL SYSTEMS PRIVATE LIMITED
NOTICE is hereby given that by an order dated 29th April 2025, the National Company Law Tribunal, Division Bench-II, Chennai ("NCLT" or "the Tribunal") has directed a meeting to be held of the Unsecured Creditors of Adonis Medical Systems Private Limited ("the Applicant Company" or "the Resulting Company" or "the Transferee Company" or "the Amalgamated Company" or "the Company") for the purpose of considering, and if thought fit, approving with or without modification, the Composite Scheme of Arrangement and Amalgamation proposed to be made between Cura Healthcare Private Limited (CIN: U51397TN2001PTC047385) and Adonis Medical Systems Private Limited (CIN: U51397TN1998PTC121627) and 3l Medical Technologies Private Limited (CIN: U33110TN2020PTC139683) and their respective shareholders and creditors ("the Scheme").
In pursuance of the said order and as directed therein, further notice is hereby given that a meeting of the Unsecured Creditors of the Company will be convened and held on **Sunday, 15 June 2025 at 10:30 A.M** through video conferencing or other audio-visual means ("VC/OAVM"). At such day, date and time, the said Unsecured Creditors of the Company are requested to attend.
The quorum for the Meeting shall be 35 (Thirty-five) in number. In case, the said quorum is not present at fixed time for meeting, the meeting shall be adjourned by half an hour and thereafter, the person(s) present for voting shall be deemed to constitute the quorum.
Copies of the said Scheme, and the Explanatory Statement required to be furnished under Section 230 and other applicable provisions of the Companies Act, 2013 can be obtained free of charge at the registered office of the Company.
Unsecured Creditors entitled to attend and vote at the meeting, shall vote through remote e-voting or through e-voting facility made available during the meeting through VC/OAVM. The procedure and instructions for attending the meeting through means of VC/OAVM and for e-voting shall be communicated separately to the e-mail ID registered with the Company shortly.
The Tribunal has appointed Mr. Jayanth Viswanathan as the Chairperson of the said Meeting and M.S.Elamathi as the Scrutinizer of the said Meeting. The above-mentioned Scheme, if approved by the Meeting, will be subject to the subsequent approval of the NCLT.
Dated this 14th May 2025 at Chennai

Jayanth Viswanathan
Chairperson appointed for the Meeting



GlaxoSmithKline Pharmaceuticals Limited
Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 • Website: <https://india-pharma.gsk.com/en-in/>
Email: in.investorquery@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025 (₹ in Lakhs)

Particulars	Standalone					Consolidated				
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
1 Revenue from continuing operations	96608	94636	91087	372349	340725	97437	94942	92980	374921	345371
2 Profit before Exceptional Items and tax	35490	30635	26631	124375	95265	35857	30810	26822	125519	95980
3 Exceptional Items [credit / (charge)]	—	—	240	469	(14361)	—	—	240	469	(14361)
4 Profit before tax	35490	30635	26871	124844	80904	35857	30810	27062	125988	81619
5 Net Profit after tax	26014	22858	19308	91906	58469	26287	22988	19448	92758	58996
6 Total comprehensive income for the period	25630	22976	19239	91640	58052	25903	23106	19379	92492	58579
7 Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8 Other Equity	—	—	—	177982	161468	—	—	—	178190	160823
9 Earnings Per Share (EPS) (of ₹ 10 each)										
Basic and diluted EPS before Exceptional Items (₹)	15.35	13.49	11.29	54.01	40.83	15.52	13.57	11.37	54.52	41.14
Basic and diluted EPS after Exceptional Items (₹)	15.35	13.49	11.39	54.24	34.51	15.52	13.57	11.48	54.76	34.83
	Not Annualised					Not Annualised				

Notes:
1. The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code.
2. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th May, 2025.
3. The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs. 32 per equity share).

Place: Mumbai
Date: 13th May, 2025

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346

